TargetMol

ABT-299

Product Code:
 
TAR-T26527
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26527-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
ABT-299 is a prodrug of A-85783.
CAS:
161395-35-3
Formula:
C32H28ClFN4O4S
Molecular Weight:
619.11
Purity:
0.98
SMILES:
[Cl-].CN(C)C(=O)n1cc(C(=O)c2ccn3[C@H](SCc23)c2ccc[n+](COC(C)=O)c2)c2ccc(cc12)-c1ccc(F)cc1

References

1. Snapper JR, Lu W, Lefferts PL, Thabes JS. Effect of platelet-activating factor-receptor antagonism on endotoxin-induced lung dysfunction in sheep. J Appl Physiol (1985). 1998 May;84(5):1610-4. PubMed PMID: 9572806. 2. Curtin ML, Davidsen SK, Heyman HR, Garland RB, Sheppard GS, Florjancic AS, Xu L, Carrera GM Jr, Steinman DH, Trautmann JA, Albert DH, Magoc TJ, Tapang P, Rhein DA, Conway RG, Luo G, Denissen JF, Marsh KC, Morgan DW, Summers JB. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists. J Med Chem. 1998 Jan 1;41(1):74-95. PubMed PMID: 9438024. 3. Negro Alvarez JM, Miralles L?pez JC, Ortiz Mart?nez JL, Abell?n Alem?n A, Rubio del Barrio R. Platelet-activating factor antagonists. Allergol Immunopathol (Madr). 1997 Sep-Oct;25(5):249-58. Review. PubMed PMID: 9395010. 4. Albert DH, Magoc TJ, Menacherry SD, Morgan DW, Sun E, Reyes AE, Kleinert HD, Carter GW, Summers JB. Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist. Inflamm Res. 1997 Jul;46(7):272-7. PubMed PMID: 9266276.